RG
Therapeutic Areas
Hikma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Authorized Generic of Nucynta® ER (tapentadol) | Pain Management | Launched |
| Authorized Generic of Nucynta® (tapentadol) | Pain Management | Launched |
| Complex Generic Injectables Portfolio | Various (Oncology Support, Anti-infectives, CNS) | ANDA Filed / Development |
| Oral Solid Dose Generics Portfolio | Various (CV, CNS, Diabetes) | ANDA Pending / Development |
| Branded Specialty Portfolio (MENA) | Oncology, Diabetes, Cardiovascular, Respiratory | Marketed / Line Extensions |
Leadership Team at Hikma
SD
Said Darwazah
Chief Executive Officer
FD
Faisal Darwazeh
Vice President, Group Business Development & Alliances
HF
Hafrun Fridriksdottir
President, Rx and R&D
NR
Nassim Rahmani
Associate Vice President, Commercial Europe & Canada
TD
Tiago Duarte
Associate Vice President, CMO & Operations, Injectables Division